When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Researchers at the School of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have found that ...

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

In this week’s edition of The Prototype, we look at new advances in fusion power, how the new budget bill undermines clean ...

Interest in autonomous agents is skyrocketing. Here, CIOs from finance, retail, and healthcare discuss how they see the ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...

Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

The combination of climate change and pathogen expansion could be fueling a surge in infectious diseases. GEN consulted ...

A patient shares how an event about clinical trials at Moores Cancer Center brought a community together to educate and ...